<DOC>
	<DOCNO>NCT00466674</DOCNO>
	<brief_summary>Donor mobilization : Donor mobilize G-CSF ( Granocyte ) sub-cutaneous 10 µg/kg/day 5 6 day . Hematopoïetic Stem Cell Harvest : By 1 , 2 , 3 aphaeresis , number 4 x 106 cellules CD34+ /kg require . If CD34+ &gt; = 2 &lt; = 4x106/kg : center must decide strategy Decision . In case insufficient graft : Bone Marrow Harvest recommend Conditioning : Fludarabine - Busulfan - ATG - D-5 : Fludarabine ( 30 mg/m² ) - D-4 : Fludarabine ( 30 mg/m² ) + Busilvex ( 0,8 mg/kg every 6 h ) - D-3 : Fludarabine ( 30 mg/m² ) + Busilvex ( 0,8 mg/kg every 6 h ) - D-2 : Fludarabine ( 30 mg/m² ) + ATG ( Genzyme ) ( 2.5 mg/Kg ) - D-1 : Fludarabine ( 30 mg/m² ) + ATG ( Genzyme ) ( 2.5 mg/Kg ) GVHD Prophylaxis : CsA alone 3 mg/ kg + Methotrexate D1 , D3 D6 case minor ABO incompatibility anti A/B antibodies titer &gt; 1/32 . Transplant : HSC D0 • 3 month Transplantation : Disease Evaluation : - If CR : Supervision . Then progression : 4 cycle Bortezomib . - If CR : Bortezomib ( 4 cycle ) • Evaluation Bortezomib cycle - If CR : Supervision . Then , progression GvHD : DLI If RC GVHD : DLI</brief_summary>
	<brief_title>Treatment Myeloma Patients &lt; = 65 Years Old With Response &gt; = 50 % After HSC Autotransplant Allogenic Transplant Genoidentical Phenoidentical After Reduced Intensity Conditioning</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Major patient guardianship Myeloma high b2 microglobulin level ( &gt; 3 mg/l ) and/or chromosome 13 deletion , and/or translocation ( 4 ; 14 ) stage I DS high evolutive potential stage II , III DS . AND With response &gt; = 50 % &lt; = 90 % first AutoHSCT ( IFM 2005 01 ) . The evaluation must perform within 2 month first AutoHSCT . HLA identical relate unrelated donor ( match 10/10 ) . Donor recipient must sign write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>RICT</keyword>
	<keyword>conditioning</keyword>
	<keyword>allograft</keyword>
</DOC>